Quick Answer
BioNexus Gene Lab Corp reported Gross Profit of $1.29 million for fiscal year 2024.
BioNexus Gene Lab Corp Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2024 | $1.29M | -3.0% |
| 2023 | $1.33M | +5.6% |
| 2022 | $1.26M | -44.5% |
| 2021 | $2.27M | +31.8% |
| 2020 | $1.72M | +2977.3% |
| 2019 | $55.9K | +94.3% |
| 2018 | $28.8K | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $377.7K | +15.7% | +2.6% |
| June 30, 2025 | $368.0K | +27.5% | +7.1% |
| March 31, 2025 | $343.5K | -5.9% | +5.2% |
| September 30, 2024 | $326.5K | -7.8% | +13.1% |
| June 30, 2024 | $288.7K | -15.0% | -20.9% |
| March 31, 2024 | $365.0K | -1.0% | +3.0% |
| September 30, 2023 | $354.3K | +18.3% | +4.3% |
| June 30, 2023 | $339.7K | +28.7% | -7.9% |
- BioNexus Gene Lab Corp showed a decrease of -3.0% in Gross Profit compared to the prior fiscal year.
- Over the 2018–2024 period, BioNexus Gene Lab Corp’s gross profit has grown by 4383.0% (from $28.8 thousand to $1.29 million).
- The most recent figure is from BioNexus Gene Lab Corp’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: